Physician profile
Heather D Lambert
NPI 1023099074
$5,509.25
in general payments reported to CMS, 2019-2025
35 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 96% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,257 · 2022: $1,085 · 2023: $929 · 2024: $1,153 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,167.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,423.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $709.06 | 2021-2025 | |
| Lilly USA, LLC | $658.27 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $368.90 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $236.51 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $232.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.15 | 2021-2024 | Trintellix |
| Corcept Therapeutics | $164.18 | 2023-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $154.79 | 2023-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $135.35 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $121.01 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.26 | 2022-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $115.64 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $99.13 | 2022 | |
| Axsome Therapeutics, INC. | $86.70 | 2025 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $77.15 | 2021-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.52 | 2021-2023 | Trulance, Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.29 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $54.67 | 2024 | Fanapt, Hetlioz |
| Amarin Pharma, INC. | $46.10 | 2021-2022 | |
| Irhythm Technologies, INC. | $42.08 | 2024 | Zio Monitor, Zio Xt Patch |
| Glaxosmithkline, LLC. | $41.33 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Sanofi Pasteur INC. | $35.24 | 2021 | |
| Amgen INC. | $35.00 | 2021 | |
| Eisai INC. | $24.71 | 2021-2022 | |
| Hologic Sales and Service, LLC | $19.74 | 2024 | Aptima |
| Lundbeck LLC | $19.21 | 2024 | Vyepti |
| Idorsia Pharmaceuticals US INC | $18.44 | 2024 | Quviviq |
| Kyowa Kirin, INC. | $17.58 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.96 | 2022 | |
| Redhill Biopharma INC. | $15.74 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.46 | 2021 | |
| Mylan Specialty L.P. | $14.22 | 2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $13.95 | 2022 | |
| Mylan Pharmaceuticals INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.